Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Nature Medicine 13, 309-312 (1 March 2007) | doi:10.1038/nm0307-309;
Tuberculosis, a neglected opportunity?
Abstract
Historically, tuberculosis (TB) has fallen firmly in the group of 'neglected diseases'—diseases in which pharmaceutical companies have been reluctant to invest due to a perception of low commercial potential. According to the World Health Organization (WHO), an estimated 1.7 million deaths resulted in 2004 from TB, and the global prevalence of TB was 14.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
